Evidence map›Paper›PMID 38430320›Full record

ArticleObesity surgery2024

Semaglutide and Tirzepatide for the Management of Weight Recurrence After Sleeve Gastrectomy: A Retrospective Cohort Study.

Mohammad Jamal, Mohsen Alhashemi, Carol Dsouza, Sara Al-Hassani, Wafa Qasem, Sulaiman Almazeedi, Salman Al-Sabah

Abstract read
PubMed Publisher
In one paragraph

Article in Obesity surgery, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed, 8 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

38 citing papers in PubMed, 8 syntheses or guidelines pooled it.

  1. Guideline
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Review
  15. Article
  16. Observational
  17. Efficacy of tirzepatide for weight loss and it's comparative effectiveness to weight loss surgery in inflammatory bowel disease.Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2026
    Article
  18. Observational
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Mohammad JamalDepartment of Organ Transplant, College of Medicine, Health Sciences Center, Kuwait University, Kuwait City, Kuwait. mohammad.jamal@mail.mcgill.ca.ORCID 0000-0003-3314-2614
Mohsen AlhashemiDepartment of Surgery, Jaber Hospital, Kuwait City, Kuwait.
Carol DsouzaDepartment of Surgery, College of Medicine, Health Sciences Center, Kuwait University, Kuwait City, Kuwait.
Sara Al-HassaniDepartment of Surgery, College of Medicine, Health Sciences Center, Kuwait University, Kuwait City, Kuwait.
Wafa QasemThe Clinic, Kuwait City, Kuwait.
Sulaiman AlmazeediDepartment of Surgery, Jaber Hospital, Kuwait City, Kuwait.
Salman Al-SabahDepartment of Surgery, Jaber Hospital, Kuwait City, Kuwait.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMetabolic and bariatric surgery (MBS) is the most effective treatment for obesity and improvement of obesity-associated comorbidities. However, a proportion of these patients may suffer from weight recurrence and recurrence of obesity-associated comorbidities.

methodA retrospective cohort study of patients who underwent SG between January 2008 and August 2022 and sought treatment for weight recurrence with semaglutide or tirzepetide from January 2022 onwards.

resultA total of 115 patients were included, of which 70 had SG and treated for weight recurrence with semaglutide and 45 had SG and treated with tirzepatide. The mean age of patients was 38.8 (10.4) and 80.9% of patients were female. The mean pre-treatment weight and BMI was 94.0 (23.8) kg and 35.1 (6.0) kg/m

conclusionShort-term outcomes show that semaglutide and tirzepatide can be an effective treatment for managing weight recurrence after SG. Studies with longer follow-up are needed to determine the durability, as weight regain after discontinuation of the medication is highly likely, and the high cost of these medications can limit their use.

Indexed as

Gastric Inhibitory PolypeptideGlucagon-Like Peptide-2 ReceptorGlucagon-Like PeptidesObesity, MorbidFemaleGastrectomyHumansMaleObesityRetrospective StudiesSemaglutideTirzepatideTreatment OutcomeWeight LossGastric Inhibitory PolypeptideGlucagon-Like Peptide-2 ReceptorGlucagon-Like PeptidesSemaglutideTirzepatideBariatric surgeryGIP/GLP1GLP1SemaglutideSleeve gastrectomyTirzepatideWeight lossWeight recurrenceWeight regain

Identifiers

PMID38430320

What OpenQuestion holds

Texttitle and abstract
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.